Charles River Laboratories’ third quarter results were met with negative market reaction, as investors focused on the company’s muted top-line growth and margin pressures. Management cited ongoing challenges in the biotech funding environment, which dampened demand from smaller clients, and the loss of a major commercial customer in the Manufacturing segment. CEO James Foster explained that “client demand has stabilized,” but acknowledged lingering end market uncertainty, particularly among mid-sized biotech customers who remain cautious amid funding constraints.

Is now the time to buy CRL? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Charles River Laboratories’s Q3 Earnings Call

• Patrick Donnelly (Citi) asked about the outlook for DSA demand given persistent book-to-bill ratios below 1.0. CEO James Foster pointed to improving proposal activity and said, “We are cautiously optimistic that booking activity for biotech clients will continue to improve.”
• David Windley (Jefferies) pressed for detail on the mix of short-term versus long-term studies in backlog and the impact on revenue timing. Foster explained that recent backlog trends suggest increasing short-term work, which could lead to faster revenue recognition.
• Elizabeth Anderson (Evercore ISI) inquired about adoption of new approach methodologies (NAMs) among client groups. Foster replied that “most of these technologies are relatively nascent,” and client uptake remains limited until scientific validation improves.
• Eric Coldwell (Baird) questioned how much of the announced $100 million in cost savings will flow to the bottom line. Interim CFO Michael Knell said it is too early to specify, but the focus is on “expanding earnings next year.”
• Casey Woodring (JPMorgan) asked if higher third-party NHP sourcing costs would pressure DSA margins next year. Knell responded that as long as demand is consistent, these costs should not be a recurring drag.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) sustained improvement in biotech funding and its impact on DSA bookings and backlog; (2) progress on the planned divestiture of non-core businesses and realization of targeted cost savings; and (3) stabilization or growth in key segments such as Microbial Solutions and Research Models and Services. Execution on NAMs adoption and customer demand trends will remain important additional drivers.

Charles River Laboratories currently trades at $173.50, down from $177.90 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free for active Edge members).

The Best Stocks for High-Quality Investors

Fresh US-China trade tensions just tanked stocks—but strong bank earnings are fueling a sharp rebound. Don’t miss the bounce.

Don’t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.